EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

High-Throughput Screening of Antiviral Compounds Using a Recombinant Hepatitis B Virus and Identification of a Possible Infection Inhibitor, Skimmianine

Mika Yoshita, Masaya Funaki iD, Tetsuro Shimakami, Masaki Kakuya, Kazuhisa Murai iD, Saiho Sugimoto, Shotaro Kawase, Koji Matsumori, Taro Kawane, Tomoki Nishikawa, Asuka Nakamura, Reo Suzuki und 12 weitere

Viruses · 2024

DOI: 10.3390/v16081346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Mika Yoshita und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8641, Japan. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B virus, High-Throughput Screening Assays, Hepatocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, Japanese Society for the Promotion of Science (JSPS) KAKENHI Grants-in-Aid for Scientific Research (B).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We developed a novel hepatitis B virus (HBV) infection-monitoring system using a luminescent, 11-amino acid reporter (HiBiT). We performed high-throughput antiviral screening using this system to identify anti-HBV compounds. After the infection of primary human hepatocytes with the recombinant virus HiBiT-HBV, which contains HiBiT at its preS1, 1262 compounds were tested in a first screening using extracellular HiBiT activity as an indicator of viral infection. Following a second screening, we focused on the compound skimmianine, which showed a potent antiviral effect. When skimmianine was added at the same time as HiBiT-HBV infection, skimmianine inhibited HiBiT activity with EC50 of 0.36 pM, CC50 of 1.67 μM and a selectivity index (CC50:EC50 ratio) of 5,100,000. When skimmianine was added 72 h after HiBiT-HBV infection, the EC50, CC50 and selectivity index were 0.19 μM, 1.87 μM and 8.79, respectively. Time-lapse fluorescence imaging analysis using another recombinant virus, ReAsH-TC155HBV, with the insertion of tetra-cysteine within viral capsid, revealed that skimmianine inhibited the accumulation of the capsid into hepatocytes. Furthermore, skimmianine did not inhibit either attachment or internalization. These results imply that skimmianine inhibits the retrograde trafficking of the virus after internalization. This study demonstrates the usefulness of the recombinant virus, HiBiT-HBV, for high-throughput screening to identify anti-HBV compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B virusHigh-Throughput Screening AssaysHepatocytesHumansHepatitis BVirus ReplicationDrug Evaluation, PreclinicalGenes, Reporter

Stichwörter der Autor:innen

hepatitis B virushigh-throughput screeningskimmianine

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Graduate School of Medicine, Kanazawa University, 13-1 Takaramachi, Kanazawa 920-8641, Japan.
  • Department of Clinical Laboratory Medicine, Graduate School of Medical Science, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa 920-0942, Japan.
  • Department of Virology II, National Institute of Infectious Diseases, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8640, Japan.

ORCID-Profile: Masaya Funaki, Kazuhisa Murai, Ying-Yi Li, Kouki Nio, Kazunori Kawaguchi, Masao Honda, Taro Yamashita

Förderung

  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Japanese Society for the Promotion of Science (JSPS) KAKENHI Grants-in-Aid for Scientific Research (B)
  • JSPS KAKENHI Grant in Aid for Early-Career Scientists
  • JSPS KAKENHI Fostering Joint International Research (B)

Zitieren

APA

Yoshita, M., Funaki, M., Shimakami, T., Kakuya, M., Murai, K., Sugimoto, S., Kawase, S., Matsumori, K., Kawane, T., Nishikawa, T., Nakamura, A., Suzuki, R., Ishida, A., Kawasaki, N., Sato, Y., Li, Y. Y., Sumiyadorj, A., Nio, K., Takatori, H., …, & Yamashita, T. (2024). High-Throughput Screening of Antiviral Compounds Using a Recombinant Hepatitis B Virus and Identification of a Possible Infection Inhibitor, Skimmianine. Viruses. https://doi.org/10.3390/v16081346

Vancouver

Yoshita M, Funaki M, Shimakami T, Kakuya M, Murai K, Sugimoto S, et al. High-Throughput Screening of Antiviral Compounds Using a Recombinant Hepatitis B Virus and Identification of a Possible Infection Inhibitor, Skimmianine. Viruses. 2024. doi:10.3390/v16081346

BibTeX
@article{Yoshita2024,
  author = {Yoshita, Mika and Funaki, Masaya and Shimakami, Tetsuro and Kakuya, Masaki and Murai, Kazuhisa and Sugimoto, Saiho and Kawase, Shotaro and Matsumori, Koji and Kawane, Taro and Nishikawa, Tomoki and Nakamura, Asuka and Suzuki, Reo and Ishida, Atsuya and Kawasaki, Narumi and Sato, Yuga and Li, Ying-Yi and Sumiyadorj, Ariunaa and Nio, Kouki and Takatori, Hajime and Kawaguchi, Kazunori and Kuroki, Kazuyuki and Kato, Takanobu and Honda, Masao and Yamashita, Taro},
  title = {High-Throughput Screening of Antiviral Compounds Using a Recombinant Hepatitis B Virus and Identification of a Possible Infection Inhibitor, Skimmianine},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16081346}
}
Kostenlos starten →